000790.Sz
The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of pharmaceutical products.
Business. The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of pharmaceutical products.
The company's capital structure is characterized by a debt-to-equity ratio of 0.53, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.78, suggesting potential challenges in meeting short-term obligations. The price-to-book ratio of 3.56 implies that the market values the company at a premium to its book value, while the negative return on equity of -44.77% highlights significant underperformance in generating returns for shareholders.
Profitability metrics reveal a stark contrast to industry norms. The company reported a net loss of CNY 320.42 million, with an operating loss of CNY 337.14 million. Gross profit of CNY 252.10 million represents a margin of 46.2%, which is relatively high but insufficient to offset the operating and net losses. The return on assets of -23.07% further underscores the company's inability to generate returns from its asset base.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The absence of segment-specific data limits the ability to assess the performance of individual product lines or markets.
The company's growth trajectory is constrained by its current financial performance. Revenue for the period was CNY 545.50 million, but the negative operating and net income suggest a lack of sustainable growth. Capital expenditures of CNY 63.04 million indicate ongoing investment, but the free cash flow of -CNY 376.70 million suggests that these investments are not yet generating positive returns. The outlook for the next fiscal year remains uncertain without significant operational improvements.
Key risk factors include liquidity constraints and the potential for dilution. The company's net cash position is negative after accounting for total debt, which could necessitate additional financing. The risk of dilution is currently assessed as low, but the company's financial performance may change this outlook if further capital raising is required. Adjustments to the valuation have been applied to reflect these risks.
Recent events, including financial filings and transcripts, have not provided significant new insights into the company's strategic direction or operational performance. The company's recent financial results highlight the need for cost management and operational efficiency improvements to address the current losses and improve shareholder returns.
- The company is experiencing significant financial losses, with a net loss of CNY 320.42 million and an operating loss of CNY 337.14 million.
- The debt-to-equity ratio of 0.53 indicates a moderate level of leverage, but the current ratio of 0.78 suggests liquidity concerns.
- The company's return on equity of -44.77% and return on assets of -23.07% highlight poor performance in generating returns.
- The company's revenue is concentrated in a single segment, increasing exposure to regional and regulatory risks.
- The company's free cash flow is negative at -CNY 376.70 million, indicating that operations are not generating sufficient cash to fund investments.
- The risk of dilution is currently low, but the company's financial performance may necessitate additional financing in the future.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 000790.SZ Market data — financials · 2026-05-26
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
4 tracked-field change(s) detected vs prior analysis; max severity: medium.
- Dilution risk— → lowlow
- Liquidity risk— → mediumlow
- Activity— → Pharmaceuticalsmedium
- Economic sector— → Healthcaremedium